Search clinical trials for: MK-3475 and BCG

Total 3520 results

Shaheen Alanee
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

Endoscopic Surgical Procedure | High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma | Transitional Epithelial Cells

United States
Southern Illinois University
Merck Sharp & Dohme LLC

Active, not recruiting

MK-3475/BCG in High Risk Superficial Bladder Cancer (MARC)

Bladder Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Norway, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Co... and more
Merck Sharp & Dohme LLC

Recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Israel, Italy, Mexico, New Zealand, Poland, Sweden, Turkey, United Kingdom, Greece, Russian Federation
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Bladder Cancer

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Recurrent Bladder Carcinoma | Stage I Bladder Cancer | Stage 0a Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

Poland, United States, Argentina, Chile, Japan, Australia, France, New Zealand, South Africa, Turkey
Merck Sharp & Dohme LLC

Completed

Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

Lymphoma | Solid Tumor

United States, Israel
Merck Sharp & Dohme LLC

Completed

A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002)

Pulmonary Arterial Hypertension

Moldova, Republic of
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Merkel Cell Carcinoma

United States, Australia, Canada, France, Italy, New Zealand, Spain, Sweden
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)

Neoplasms | Colorectal Cancer

United States, Canada
Merck Sharp & Dohme LLC

Recruiting

MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Korea, Republic of, Australia, Germany, Spain, Italy, Switzerland, France, Argentina, Colombia, Israel, Austria, Mexico, United Kingdom, Belgium, Turkey, Peru, South Africa
Merck Sharp & Dohme LLC

Completed

MK-5475 in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

Pulmonary Hypertension

United States, Israel, Moldova, Republic of
Merck Sharp & Dohme LLC

Withdrawn

MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)

Pneumonia | Coronavirus Disease 2019 (COVID-19) | Hypoxemia
Merck Sharp & Dohme LLC

Completed

Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)

Solid Neoplasms

United States, Canada, Israel, Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Non-small Cell Lung Cancer | Solid Tumors | Castration Resistant Prostate Cancer | Microsatellite Stable Colorectal Cancer

Canada, United States, Australia, Israel, Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Colorectal Neoplasms

United States, Canada
Merck Sharp & Dohme LLC

Completed

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Advanced/Metastatic Solid Tumors

United States, Canada
Merck Sharp & Dohme LLC

Terminated

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Advanced Solid Tumor
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Neoplasm

United States, Canada, Israel
Sarcoma Alliance for Research through Collaboration
Merck Sharp & Dohme LLC

Completed

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

Soft Tissue Sarcoma | Bone Sarcoma

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)

Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer (PANACEA)

Metastatic Breast Cancer

France, Austria, Belgium, Australia, Italy
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Malignant Ovarian Clear Cell Tumor

United States, Puerto Rico
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Solid Tumor | Other Cancer | Advanced Malignant Neoplasm | Locally Advanced

United States, Spain, Korea, Republic of, Australia, France, Germany, Italy, Singapore, United Kingdom
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

rrCLL | rrMM | rrDLBCL
Merck Sharp & Dohme LLC

Completed

Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)

Non-Small-Cell Lung Cancer
Nasser Hanna, M.D.
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Terminated

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Genital Neoplasms, Female | Testicular Neoplasms | Genital Neoplasms, Male | Ovarian Neoplasms | Mediastinal Neoplasms | Germ Cell Neoplasms | Non Seminomatous Germ Cell Tumors

United States
PETHEMA Foundation
Merck Sharp & Dohme LLC; Adknoma Health Research

Completed

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Multiple Myeloma

Spain
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

MSI Positive Colorectal Cancer | MSI Negative Colorectal Cancer | MSI Positive Non-Colorectal Cancers

United States
MedSIR

Terminated

Checkpoint Blockade in COVID-19 Pandemic (COPERNICO)

COVID-19 | Pneumonia, Viral

Spain
Institut de Recherches Internationales Servier
Merck Sharp & Dohme LLC

Recruiting

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma

Astrocytoma

United States
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC) (PRIMUS)

Metastatic Squamous Non-small Cell Lung Cancer

Germany
Erasmus Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab (RESPONDER)

Biomarkers | Transitional Cell Carcinoma of the Bladder

Netherlands
Fox Chase Cancer Center
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab in Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Medullary Thyroid Cancer (MTC)

United States
Center Trials & Treatment

No longer available

Expanded Access for Pembrolizumab (MK-3475)

Glioblastoma Multiforme | Melanoma (Skin) | Melanoma Recurrent | Glioma of Brain | Glioblastoma by Gene Expression Profile

Hong Kong, Belarus, Tajikistan, Uzbekistan
Kindai University
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab as Neoadjuvant Treatment in HCC

Hepatocellular Carcinoma
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)

Melanoma
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Completed

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Brain Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Fox Chase Cancer Center
Merck Sharp & Dohme LLC

Terminated

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Lymphoma, T-Cell, Peripheral

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Melanoma | Lymphoma | Head and Neck Cancer | Gastric Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Lung Cancer | Bladder Cancer | Endometrial Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | UC (Urothelial Cancer) | Microsatellite-instability (MSI) High Colorectal...

United States
Assistance Publique - Hôpitaux de Paris

Completed

Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin (CARSKIN)

Carcinoma, Squamous Cell

France
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

Melanoma | Carcinoma, Non-Small-Cell Lung

India
Lynn Feun, MD
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Aduro Biotech, Inc.
Merck Sharp & Dohme LLC

Terminated

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

Malignant Pleural Mesothelioma

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)

Esophageal Carcinoma | Esophagogastric Junction Carcinoma
St. Louis University

Completed

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (NeoPembroMel)

Melanoma | Metastatic Melanoma | Stage IV Melanoma | Unresectable Malignant Neoplasm | Stage III Melanoma

United States

Search clinical trials for: MK-3475 and BCG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations